On Thursday 16 December, the European Medicines Agency (EMA) recommended the use of two new treatments for Covid-19: - Xevudy (sotrovimab), the monoclonal antibody developed by GSK (see EUROPE B12835A21); - Kineret (anakinra), an immunosuppressive drug previously authorised in the EU for the treatment of inflammatory conditions.
The EMA says that Xevudy is intended for the treatment of Covid-19 in adults and adolescents aged 12 years and over who are at increased risk of developing a severe...